Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Immix Biopharma, Inc. - Common Stock
(NQ:
IMMX
)
9.510
-0.130 (-1.35%)
Delayed Quote
Updated: 2:44 PM EDT, Oct 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immix Biopharma, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
September 19, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
August 28, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
IMMX Stock Earnings: Immix Biopharma Beats EPS for Q2 2024
↗
August 12, 2024
IMMX stock results show that Immix Biopharma beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
July 08, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
June 17, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
IMMX Stock Earnings: Immix Biopharma Beats EPS for Q1 2024
↗
May 13, 2024
IMMX stock results show that Immix Biopharma beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
April 29, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma on Track to Dose NXC-201 Patients in United States
April 18, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
IMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023
↗
April 02, 2024
IMMX stock results show that Immix Biopharma missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
March 20, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
March 05, 2024
Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words
From
Immix Biopharma, Inc.
Via
GlobeNewswire
BioMedNewsBreaks — Immix Biopharma Inc. (NASDAQ: IMMX) Closes on $15M Public Offering
February 09, 2024
Via
Investor Brand Network
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
February 08, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
February 07, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
February 05, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Proposed Public Offering of Common Stock
February 05, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
January 25, 2024
Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
January 25, 2024
Via
Benzinga
Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
January 24, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board
January 04, 2024
Dr. Sanchorawala co-authored landmark study of daratumumab (DARZALEX®) in AL Amyloidosis published in The New England Journal of Medicine, 2021 that led to it becoming a first-line standard of care
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board
December 18, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
↗
December 15, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
December 14, 2023
Via
Benzinga
Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023
December 11, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit
November 30, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis
November 22, 2023
Virtual Event to be held on November 29, 2023 at 4:15 p.m. ET
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing
November 21, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients
November 06, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients
November 06, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board
October 26, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
